{"data":[{"catalyst_id":990001,"drug_name":"SAMPLIMAB","company":"Sample Therapeutics, Inc.","ticker":"XSMPL","tickers":["XSMPL","XPRTN"],"cik":"0009999001","indication":"sample indication (moderate-to-severe examplitis)","application_number":"BLA999901","pdufa_date":"2026-11-15","stage":"set","confidence":"high","date_confidence":"confirmed","authority":"llm_high","source_quote":"The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of November 15, 2026 for SAMPLIMAB. [FICTIONAL SAMPLE — not a real filing sentence]","source_accession":"0009999001-26-000001","source_url":"https://www.sec.gov/Archives/edgar/data/9999001/000999900126000001/0009999001-26-000001-index.htm","last_updated":"2026-07-20T14:02:11.000000+00:00","age_days":12},{"catalyst_id":990002,"drug_name":"EXTENDIVIR","company":"Extendia Pharma plc","ticker":"XEXTD","tickers":["XEXTD"],"cik":"0009999002","indication":"sample indication (chronic placeholder syndrome)","application_number":"NDA999902","pdufa_date":"2026-10-05","stage":"extended","confidence":"high","date_confidence":"confirmed","authority":"human_lock","source_quote":"The FDA extended the PDUFA goal date by three months to October 5, 2026 to review recently submitted additional information. [FICTIONAL SAMPLE — not a real filing sentence]","source_accession":"0009999002-26-000007","source_url":"https://www.sec.gov/Archives/edgar/data/9999002/000999900226000007/0009999002-26-000007-index.htm","last_updated":"2026-06-30T09:15:44.000000+00:00","age_days":32},{"catalyst_id":990004,"drug_name":"MINIMALIN","company":"Minimal Biosciences AG","ticker":null,"tickers":[],"cik":null,"indication":null,"application_number":null,"pdufa_date":"2026-09-01","stage":"set","confidence":null,"date_confidence":"confirmed","authority":"human_lock","source_quote":null,"source_accession":null,"source_url":null,"last_updated":null,"age_days":null}],"meta":{"total":3,"limit":200,"next_since":null,"has_more":null}}